HOME
LOGIN
THE MEDICAL LETTER
Subscribe
Current Issue
Previous Issues
Reference Tables
ABOUT US
The Medical Letter, Inc.
CONTINUING EDUCATION
Exams
DRUG INTERACTIONS
CONTACT US
The Medical Letter Mobile Home Page
CURRENT
ISSUE
1561
The FDA has approved baloxavir marboxil (Xofluza – Shionogi/Genentech), the first polymerase acidic (PA) endonuclease inhibitor, for single-dose, oral treatment of acute uncomplicated influenza in patients ≥12 years old. Baloxavir is the first drug with a new mechanism of action to be approved for treatment of influenza in almost 20...  read more...
More from issue 1561
Coming Soon
Drugs for Chronic Insomnia
Drugs for Cough
Tildrakizumab (Ilumya) - Another IL-23 Inhibitor for Psoriasis
Antiviral Drugs for Seasonal Influenza 2018-2019
Dupilumab (Dupixent) for Asthma
Recommend to Your Library  

We're Essential.   Begin your free trial  
Previous Issues
© 2018 The Medical Letter, Inc.